These include: anti-RAGE antibodies, sRAGE, and RAGE inhibitors; FPSZM1, a specific and potent chemical inhibitor of AGE receptor, which could improve diabetic nephropathy [96] and Aβ-mediated brain disorder [97]; Azeliragon, an oral small molecule antagonist of RAGE in Phase 3 development for mild cognitive impairment [98]. Here, AGER is linked to brain disorder.